Brigham and Women's Hospital Aug 30 2024 Patients taking semaglutide injections are less likely to die of any cause, including from cardiovascular disease and infections like COVID-19, an international study led by researchers from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, finds. The randomized, controlled SELECT Trial, funded by Novo Nordisk, studied the effect of once-weekly semaglutide shots versus placebo on mortality in over 17,000

Tag-uri: Coronavirus